{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:25:57Z","timestamp":1790738757625,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ejca.2019.10.027","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T16:55:19Z","timestamp":1576169719000},"page":"38-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2516-5181","authenticated-orcid":false,"given":"Teresa M.S.","family":"Amaral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Sinnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Niessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"S\u00fclberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0019-2770","authenticated-orcid":false,"given":"Thomas K","family":"Eigentler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.10.027_bib1","first-page":"93","article-title":"The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.ejca.2019.10.027_bib2","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.ejca.2019.10.027_bib3","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.027_bib4","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American Joint committee on cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2019.10.027_bib5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2016.10.018","article-title":"Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013","volume":"76","author":"Landow","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2019.10.027_bib6","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/jid.2014.452","article-title":"More people die from thin melanomas (1 mm) than from thick melanomas (>4 mm) in Queensland, Australia","volume":"135","author":"Whiteman","year":"2015","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.ejca.2019.10.027_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/CLEP.S99021","article-title":"Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe \u2013 a systematic review of the literature","volume":"8","author":"Svedman","year":"2016","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ejca.2019.10.027_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-018-0048-5","article-title":"The new era of adjuvant therapies for melanoma","volume":"15","author":"Eggermont","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.027_bib9","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.10.027_bib10","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.10.027_bib11","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.10.027_bib12","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1016\/S1470-2045(18)30596-5","article-title":"Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?","volume":"19","author":"Grob","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.10.027_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ctrv.2018.06.003","article-title":"It is finally time for adjuvant therapy in melanoma","volume":"69","author":"Napolitano","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2019.10.027_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1586\/14737159.2016.1126511","article-title":"Prognostic and predictive biomarkers in melanoma: an update","volume":"16","author":"Foth","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.ejca.2019.10.027_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2019.10.027_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2019.10.027_bib17","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.10.027_bib18","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1634\/theoncologist.2016-0456","article-title":"Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma","volume":"22","author":"Daud","year":"2017","journal-title":"The Oncologist"},{"key":"10.1016\/j.ejca.2019.10.027_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/CAD.0000000000000628","article-title":"Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands","volume":"29","author":"Franken","year":"2018","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejca.2019.10.027_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2016.06.002","article-title":"Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges","volume":"48","author":"Tartari","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2019.10.027_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pky032","article-title":"A prognostic gene signature expressed in primary cutaneous melanoma: synergism with conventional staging","volume":"2","author":"Brunner","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.ejca.2019.10.027_bib22","doi-asserted-by":"crossref","first-page":"9560","DOI":"10.1200\/JCO.2017.35.15_suppl.9560","article-title":"Validation, in silico and in\u00a0vitro, of a gene-signature based risk score in cutaneous melanoma","volume":"35","author":"Brunner","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.027_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e21037","article-title":"Gene-signature based prediction of relapse-free survival in melanoma patients with known sentinel lymph node status","volume":"35","author":"Gambichler","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.027_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00432-012-1322-z","article-title":"A nine-gene signature predicting clinical outcome in cutaneous melanoma","volume":"139","author":"Brunner","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.027_bib25","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1158\/1538-7445.AM10-4652","article-title":"Abstract 4652: identification and validation of a novel nine-gene signature predicting clinical outcome in malignant melanoma","volume":"70","author":"Brunner","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2019.10.027_bib26","series-title":"R: a language and environment for statistical computing","isbn-type":"print","author":"R Development Core Team","year":"2008","ISBN":"https:\/\/id.crossref.org\/isbn\/3900051070"},{"key":"10.1016\/j.ejca.2019.10.027_bib27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/bjc.2012.306","article-title":"Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis","volume":"107","author":"Weide","year":"2012","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2019.10.027_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2019.10.027_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086194","article-title":"Survival according to BRAF-V600 tumor mutations \u2013 an analysis of 437 patients with primary melanoma","volume":"9","author":"Meckbach","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2019.10.027_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2019.10.027_bib31","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.1200\/JCO.2016.34.15_suppl.9502","article-title":"Genomic analysis and 3-y efficacy and safety update of COMBI-d: a phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E\/K-mutant cutaneous melanoma","volume":"34","author":"Flaherty","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.027_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw379.03","article-title":"Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone","volume":"27","author":"Yan","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.10.027_bib33","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2019.10.027_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy424.053","article-title":"LBA43Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600\u2013mutant stage III melanoma","volume":"29","author":"Long","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.10.027_bib35","doi-asserted-by":"crossref","first-page":"9581","DOI":"10.1200\/JCO.2016.34.15_suppl.9581","article-title":"Performance of a 31-gene expression profile in a previously unreported cohort of 334 cutaneous melanoma patients","volume":"34","author":"Zager","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.027_bib36","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jaad.2015.01.009","article-title":"Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy","volume":"72","author":"Gerami","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2019.10.027_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","article-title":"Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma","volume":"21","author":"Gerami","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2019.10.027_bib38","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1158\/1078-0432.CCR-18-2847","article-title":"Validation of melanoma immune profile (MIP), a prognostic immune gene prediction score for stage II-III melanoma","volume":"25","author":"Gartrell","year":"2019","journal-title":"Clin Cancer Res: Off J Am Assoc Canc Res"},{"key":"10.1016\/j.ejca.2019.10.027_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2010.09.772","article-title":"Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry","volume":"66","author":"Leiter","year":"2012","journal-title":"J Am Acad Dermatol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919307993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919307993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:25:35Z","timestamp":1760732735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919307993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":39,"alternative-id":["S0959804919307993"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.10.027","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}